Phase 2 trial of Allovectin-7 in advanced metastatic melanoma

Melanoma Research

Volumn 16, Issue 6, 2006, Pages 521-526

  Gonzalez, Rene ^a,f   Hutchins, Laura ^b   Nemunaitis, John ^c,g   Atkins, Michael ^d   Schwarzenberger, Paul O ^e  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e LOUISIANA STATE UNIVERSITY   (United States)

^f Anshutz Cancer Pavilion   (United States)

^g Mary Crowley Medical Research Center   (United States)

Author keywords

Allovectin 7; HLA B7; Immunotherapy; Plasmid DNA

Indexed keywords

ALLOVECTIN 7; BETA 2 MICROGLOBULIN; HLA B7 ANTIGEN; LIPID; PLASMID DNA;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASCITES; ASTHENIA; BLEEDING; BONE PAIN; CANCER SURVIVAL; CLINICAL TRIAL; COUGHING; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; ERYTHEMA; FEMALE; FEVER; FLATULENCE; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYDROCEPHALUS; HYPOTENSION; INJECTION SITE EDEMA; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE PAIN; INJECTION SITE REACTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PRURITUS; RASH; RHINITIS; SIDE EFFECT; SKIN DISCOLORATION; SKIN ULCER; TREATMENT RESPONSE; VASODILATATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; DNA; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INJECTIONS, INTRALESIONAL; LIPIDS; LIPOSOMES; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 33845575627     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000232299.44902.41     Document Type: Article

References (19)

1. Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 1997; 9:205-213.
2. Sober AJ. Cutaneous melanoma: opportunity for cure. CA Cancer J Clin 1991; 41:197-199.
3. Quirt IC, Shelly WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials. J Clin Oncol 1991; 9:729-735.
4. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12:1036-1044.
5. Sabel M, Sondak V. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist 2003; 8:451-458.
6. Atkins MB. Interleukin-2 in metastatic melanoma: what is the current role? Cancer J Sci Am 2000; 6 (Suppl 1):S8-S10.
7. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
8. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
9. Lew D, Parker SE, Latimer T, Abai AM, Kuwahara-Rundell A, Doh SG, et al. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995; 6:553-564.
10. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994; 269:2550-2561.
11. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2:85-95.
12. Nouri AM, Hussain RF, Dos Santos AV, Mansouri M, Oliver RT, et al. Intensity of class I antigen expression on human tumour cell lines and its relevance to the efficiency of non-MHC-restricted killing. Br J Cancer 1993; 67:1223-1228.
13. Vanky F, Klein E. Requirement of MHC class I antigen expression on human tumors for in vitro recognition by autologous blood lymphocytes. Semin Cancer Biol 1991; 2:55-62.
14. Ruiter DJ, Mattijssen V, Broecker ES, Ferrone S, et al. MHC antigens in human melanomas. Semin Cancer Biol 1991; 2:35-45.
15. Lanuti M, Rudginsky S, Force SD, Lambright ES, Siders WM, Chang MY, et al. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 2000; 60:2955-2963.
16. Rudginsky S, Siders W, Ingram L, Marshall J, Scheule R, Kaplan J, et al. Antitumor activity of cationic lipid complexed with immunostimulatory DNA. Mol Ther 2001; 4:347-355.
17. Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997; 15:341-349.
18. The World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: WHO Offset Publication; No. 48, 1979.
19. Atkins M. Management of stage IV melanoma. ASCO Educational Book, Thirty-Eight Annual Meeting; 2002. pp. 175-183.